Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00652483 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study of Brimonidine in Patients With Glaucoma or Ocular Hypertension
A Phase 3 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 3
- Development phase
- 433
- Enrollment target
NCT00652483 is a Phase 3 study that has completed, run by Allergan. The registered enrollment target is 433 participants.
The verdict
NCT00652483, a Phase 3 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 433 participants
- Enrollment target
Study Summary
This study evaluates the safety and efficacy of brimonidine 0.1% ophthalmic solution compared with brimonidine 0.2% ophthalmic solution in patients with glaucoma or ocular hypertension
Interventions
- DRUG Brimonidine ophthalmic solution 0.1%
- DRUG Brimonidine ophthalmic solution 0.2%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 433 participants |
| Start Date | 2003-05 |
| Est. Completion | 2004-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00652483
The ClinicalTrials.gov registry entry for NCT00652483 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 433 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Brimonidine ophthalmic solution 0.1% is the first listed.
NCT00652483 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00652483 about?
NCT00652483 is a clinical study titled "Safety and Efficacy Study of Brimonidine in Patients With Glaucoma or Ocular Hypertension". This study evaluates the safety and efficacy of brimonidine 0.1% ophthalmic solution compared with brimonidine 0.2% ophthalmic solution in patients with glaucoma or ocular hypertension
What is the current status of trial NCT00652483?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 433 participants. The study started on 2003-05. Estimated completion is 2004-09.
What interventions are being tested in trial NCT00652483?
The interventions under investigation include: Brimonidine ophthalmic solution 0.1% (DRUG), Brimonidine ophthalmic solution 0.2% (DRUG).
Who is sponsoring clinical trial NCT00652483?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.